Other studies are currently evaluating the efficacy of other SGLT1/2 inhibitors in MASH, e.g., the ELIVATE study (NCT04065841) with licogliflozin alone or combined with the agonist of the BAs receptor FXR tropifexor on fibrosis and/or NAS score in patients with MASH and fibrosis stage 2 or 3. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.